Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
|Articles|November 1, 1998
Supplements and Featured Publications
- Chronic Viral Hepatitis in the Era of Managed Care
- Volume 4
- Issue 12 Suppl
Bibliography
Advertisement
Articles in this issue
almost 28 years ago
Participating Facultyalmost 28 years ago
An Overview of Viral Hepatitisalmost 28 years ago
Viral Hepatitis: Impact, Treatment, and Costsalmost 28 years ago
New Epidemiologic Data on Hepatitis B and Calmost 28 years ago
Appropriate Screening and Early Diagnosis of Hepatitis B and Calmost 28 years ago
Clinical Utility of HCV RNA Monitoring for Patients with Chronic Hepatitis Calmost 28 years ago
State-of-the-Art Interferon Therapy for Chronic Viral Hepatitisalmost 28 years ago
Cost Effectiveness of Treating Chronic Hepatitis B and Calmost 28 years ago
Chronic Hepatitis C: An Overviewalmost 28 years ago
Chronic Hepatitis C: Impact, Diagnosis, and TreatmentAdvertisement
Related to this article
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.
Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
3
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
4
Semaglutide Adherence Falls Once Out-of-Pocket Costs Top $75 a Month
5